Clexane® is an anticoagulant of the low-molecular-weight heparin (LMWH) class, derived from natural porcine heparin, to treat thrombosis1.


Clexane is available in two different devices as seen below. There are several different doses of CLEXANE, so the syringes may look slightly different from the ones shown here.

ERIS - One step device

Eris - one step device

Automatic release of the safety mechanism when the plunger is fully depressed.

Needle completely covered by the protection cap immediately after the injection.

PREVENTIS - Two step device

Preventis 40mg - two step device

Release of the safety mechanism when the plunger is depressed after the injection.

An audiable “click” confirms the activation of the safety mechanism.

You will find the instructions of how to use Clexane and more information in the material below.

Dosage and Administration guide

Clexane dosage and administration guide - HCP



The prophylaxis of venous thromboembolism (VTE)2:

  • In moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
  • In medical patients with an acute illness and reduced mobility at increased risk of VTE.

The treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery2:

  • Prevention of thrombus formation in extracorporeal circulation during haemodialysis.
  • Acute coronary syndrome:
    • Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
    • Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

Mechanism of action

Clexane® exerts its anticoagulant effect by preventing the formation of blood clots through binding to antithrombin, a naturally occurring coagulation inhibitor and potentiating its action3.

Antithrombin is a natural inhibitor of the coagulation factors FXIa, FIXa, FXa and FIIa (thrombin)3.

Clexane® forms a complex with antithrombin. This complex undergoes a conformational change; in its altered conformation, the complex inhibits FXa, which is the primary mechanism of action. It also inhibits FIIa, although to a lesser extent - in vitro, Clexane has a high anti-Xa activity and low anti-IIa or anti thrombin activity, with a ratio of 3.62.


You can request a representative sales to contact you on the link Request a call or fill the required information on the link Keep in touch with Sanofi.


  1. Sanofi. Clexane Patient Information Leaflet, September 2020.
  2. Clexane Pre-filled Syringes Summary of Product Characteristics. May 2020. Please consult the SmPC for full information.
  3. Carter NJ, McCormack PL, Plosker GL (2008). Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs, 68:691–710.

MAT-GB-2100351 (v3.0) August 2021